larg
surfac
area
immunolog
compet
mucos
tissu
attract
administr
target
site
vaccin
import
characterist
mucos
vaccin
abil
elicit
local
immun
respons
act
infect
site
pathogen
entri
howev
mucos
surfac
endow
potent
sophist
toler
mechan
prevent
immun
system
overreact
mani
environment
antigen
henc
mucos
vaccin
may
suppress
immun
system
instead
induc
protect
immun
respons
therefor
mucos
adjuv
andor
special
antigen
deliveri
system
well
appropri
dosag
form
requir
order
develop
potent
mucos
vaccin
wherea
oral
nasal
pulmonari
vaccin
deliveri
strategi
describ
extens
sublingu
buccal
rout
receiv
consider
less
attent
review
characterist
approach
sublingu
buccal
vaccin
deliveri
describ
compar
mucos
vaccin
deliveri
site
discuss
recent
progress
highlight
promis
develop
search
vaccin
formul
includ
adjuv
suitabl
dosag
form
like
critic
design
success
sublingu
buccal
vaccin
final
outlin
challeng
hurdl
overcom
formul
issu
relev
sublingu
buccal
vaccin
deliveri
among
public
health
intervent
vaccin
far
effect
strategi
maintain
popul
health
combat
infecti
diseas
especi
develop
countri
disast
area
vaccin
save
million
live
everi
year
bring
numer
social
econom
benefit
sinc
vast
major
pathogen
infect
host
mucosa
ideal
vaccin
induc
protect
immun
mucos
site
order
act
first
line
defens
infect
howev
vaccin
current
use
administ
via
inject
eg
via
subcutan
intramuscular
rout
gener
induc
poor
mucos
immun
wherea
vaccin
administ
via
mucos
rout
proven
effect
induct
system
local
immun
addit
mucos
immun
make
vaccin
deliveri
easier
safer
parenter
administr
rout
suitabl
mass
immun
pandem
situat
improv
accept
especi
among
children
despit
advantag
mention
current
mucos
vaccin
human
use
market
reason
mucos
vaccin
pose
sever
challeng
immun
regul
toler
well
overcom
fast
remov
vaccin
bodi
fluid
enzym
review
oral
nasal
pulmonari
rout
compar
abovement
tradit
mucos
rout
sublingu
buccal
vaccin
administr
receiv
less
attent
mani
year
rout
use
deliveri
lowmolecularweight
drug
bloodstream
current
vaccin
wide
use
deliveri
via
oral
mucosa
therapeut
sublingu
allergi
vaccin
vaccin
use
sublingu
immunotherapi
slit
treat
allerg
hypersensit
sublingu
deliveri
allergen
activ
regulatori
cell
suppress
undesir
immun
reaction
result
sever
approv
sublingu
product
allergi
immunotherapi
allergi
vaccin
review
valenta
et
al
beyond
scope
review
sinc
aim
immun
regul
toler
instead
activ
adapt
immun
system
review
describ
potenti
limit
sublingu
buccal
mucosa
vaccin
deliveri
site
mucos
immun
respons
induc
upon
sublingu
buccal
vaccin
current
statu
sublingu
buccal
vaccin
deliveri
discuss
suitabl
vaccin
antigen
potent
adjuv
immun
potenti
andor
deliveri
system
highlight
appropri
dosag
form
requir
success
sublingu
buccal
vaccin
also
outlin
final
forthcom
perspect
given
includ
exist
research
develop
gap
field
potenti
improv
control
releas
vaccin
formul
sublingu
buccal
vaccin
deliveri
mucos
vaccin
deliveri
mouth
subdivid
sublingu
buccal
deliveri
sublingu
deliveri
occur
via
mucosa
ventral
surfac
tongu
floor
mouth
tongu
wherea
buccal
deliveri
occur
via
buccal
mucosa
locat
cheek
gum
upper
lower
inner
lip
fig
specif
structur
cell
composit
sublingu
buccal
region
mouth
defin
whether
less
suitabl
vaccin
deliveri
describ
within
oral
caviti
mucos
region
line
keratin
stratifi
epithelium
gingiv
hard
palat
outer
lip
wherea
region
line
nonkeratin
stratifi
epithelium
fig
epithelium
support
basement
membran
separ
two
major
layer
oral
mucosa
epithelium
underli
connect
tissu
lamina
propria
arrang
hard
palat
gingiv
includ
pluristratifi
keratin
mucos
epithelium
lamina
propria
anchor
onto
periostium
underli
bone
make
region
chemic
mechan
resist
withstand
shear
forc
associ
chew
food
floor
mouth
inner
surfac
lip
cheek
ventral
side
tongu
cover
nonkeratin
epithelium
render
rel
elast
perviou
keratin
mucosa
thu
potenti
suitabl
drug
antigen
deliveri
epithelium
serv
mechan
barrier
protect
underli
tissu
consist
basal
layer
intermedi
layer
superfici
layer
basal
superfici
layer
cell
becom
larger
flatten
proteinac
form
protein
monofila
less
viabl
due
absenc
organel
fig
compact
flatten
cell
lower
superfici
intermedi
layer
form
major
physic
barrier
transport
wherea
intercellular
lipid
play
import
role
permeabl
mucosa
besid
epitheli
cell
oral
mucos
epithelium
also
contain
three
cell
type
basal
layer
includ
merkel
cell
endocrin
cell
associ
nerv
fiber
contribut
overal
barrier
function
epithelium
also
suggest
play
role
regen
process
oral
mucosa
suprabas
layer
contain
two
type
cell
melanocyt
produc
pigment
melanin
thu
respons
color
mucosa
langerhan
cell
lc
superfici
antigenpres
cell
import
target
induct
immun
respons
antigenpres
cell
mucosa
myeloid
dendrit
cell
mdc
locat
along
lamina
propria
plasmacytoid
dc
pdc
found
submucos
tissu
fig
salivari
gland
locat
mucosa
mouth
produc
mucin
major
compon
mucu
layer
mucos
surfac
help
promot
product
secret
saliva
saliva
need
moisten
lubric
mucosa
assist
masticatori
process
bind
food
bolu
prior
swallow
addit
salivari
secret
protect
oral
epithelium
potenti
harm
substanc
regul
composit
oral
microbi
flora
enzym
activ
maintain
oral
ph
sublingu
buccal
mucosa
attract
vaccin
deliveri
site
may
advantag
rout
anatomi
physiolog
tabl
show
overview
characterist
differ
site
investig
vaccin
deliveri
dermal
deliveri
site
includ
contain
compar
featur
buccal
sublingu
site
presenc
lc
main
target
vaccin
antigen
howev
dermal
vaccin
disadvantag
imperm
thick
keratin
stratum
corneum
act
physiolog
barrier
diffus
antigen
reach
lc
topic
administr
result
dermal
vaccin
gener
need
chemic
disrupt
andor
microneedl
penetr
wall
order
let
antigen
reach
lc
induc
immun
respons
contrast
sublingu
buccal
mucosa
suitabl
vaccin
deliveri
lack
keratin
epithelium
compar
gastrointestin
mucos
rout
degrad
gastric
fluid
gastrointestin
enzym
avoid
sublingu
buccal
deliveri
although
enzymat
activ
present
mouth
mucos
rout
special
gateway
socal
microfold
cell
present
epithelium
cover
follicl
mucos
tissu
cell
take
care
transport
antigen
mucosaassoci
lymphoid
tissu
malt
peyer
patch
pp
nasopharynxassoci
lymphoid
tissu
nalt
bronchusassoci
lymphoid
tissu
balt
import
induct
antigen
deliveri
antigen
present
follow
sublingu
buccal
vaccin
upon
vaccin
deliveri
antigen
like
captur
langerhan
cell
lc
within
mucosa
myeloid
dendrit
cell
mdc
along
lamina
propria
antigenbear
dc
migrat
drain
lymph
node
interact
cell
support
differenti
effector
cell
ie
helper
th
cytotox
cell
ctl
therebi
induct
adapt
immun
respons
compar
rout
sublingu
buccal
rout
potenti
induc
mucos
immun
respons
broad
rang
tissu
tabl
describ
detail
section
mucos
immun
respons
nagai
et
al
recent
report
transport
sublingu
antigen
across
sublingu
ductal
epitheli
cell
ductal
apc
mice
sinc
differ
studi
fail
detect
specif
sampl
cell
mlike
structur
sublingu
buccal
mucosa
seem
like
antigen
cross
ductal
epithelium
via
paracellular
transcellular
pathway
probabl
effici
vaccin
deliveri
via
rout
directli
relat
permeabl
mucos
membran
permeabl
influenc
thick
degre
keratin
membran
thick
human
buccal
mucosa
estim
rang
wherea
mucos
thick
sublingu
region
term
permeabl
sublingu
region
permeabl
buccal
region
turn
permeabl
palat
region
fig
sublingu
administr
provid
rapid
uptak
macromolecul
thu
appear
attract
rout
dosag
form
short
deliveri
period
develop
sublingu
buccal
vaccin
presenc
saliva
taken
account
although
saliva
may
use
releas
antigen
certain
dosag
form
disadvantag
sinc
salivari
composit
ph
flow
rate
variabl
excess
secret
salivari
flow
may
dilut
antigen
lead
swallow
dosag
form
antigen
absorb
mucosa
socal
saliva
washout
moreov
presenc
digest
enzym
could
lead
degrad
antigen
sinc
ph
critic
paramet
antigen
absorpt
ph
valu
differ
oral
mucos
site
kept
mind
success
vaccin
deliveri
exampl
adult
ph
floor
mouth
wherea
buccal
region
howev
factor
diet
saliva
flow
rate
may
affect
ph
oral
mucosa
section
dosag
form
describ
differ
way
circumv
challeng
characterist
sublingu
buccal
vaccin
deliveri
unlik
small
synthet
drug
vaccin
antigen
reach
bloodstream
enter
sublingu
buccal
mucosa
rather
captur
antigenpres
dc
mainli
lc
mucosa
antigen
uptak
process
present
epitop
cell
antigenpres
cell
requir
induc
effect
adapt
immun
exampl
ovalbumin
antigen
cross
epitheli
barrier
within
min
uptak
sublingu
dc
occur
within
min
sublingu
administr
mice
rare
proinflammatori
cell
ie
histaminecontain
mast
cell
mc
eosinophil
eo
fig
found
oral
tissu
cell
mainli
spread
muscular
layer
beneath
mucosa
therefor
like
antigen
mainli
captur
lc
oral
dc
upper
layer
prior
reach
proinflammatori
cell
rel
high
frequenc
lc
low
number
mast
cell
buccal
region
make
buccal
mucosa
attract
site
vaccin
deliveri
despit
thicker
epithelium
lower
permeabl
compar
sublingu
mucosa
antigenbear
dc
migrat
lymph
node
drain
sublingu
buccal
area
abl
prime
cell
fig
cell
exampl
eriksson
et
al
report
substanti
number
dc
leav
buccal
epithelium
topic
buccal
immun
migrat
drain
lymph
node
present
process
antigen
lymphocyt
anoth
studi
reveal
buccal
epithelium
induct
site
effici
prime
lymphocyt
upon
activ
b
cell
leav
site
initi
antigen
present
enter
circul
dispers
select
mucos
site
differenti
memori
effector
cell
activ
lymphocyt
lead
induct
antigenspecif
helper
th
cell
andor
regulatori
cell
treg
mediat
immun
respons
fig
wherea
cell
facilit
induct
cytotox
lymphocyt
ctl
respons
fig
tissu
destin
cell
appear
larg
determin
sitespecif
integrin
suppos
home
receptor
surfac
bind
mucos
tissuespecif
receptor
addressin
vascular
endotheli
cell
recent
work
hervouet
et
al
demonstr
antigenbear
dc
captur
antigen
sublingu
mucosa
encount
distant
lymph
node
spleen
follow
sublingu
immun
mice
suggest
sublingu
dc
capabl
enter
blood
circul
seed
distant
lymphoid
organ
migrat
immun
cell
induct
malt
distant
effector
tissu
cellular
basi
socal
common
mucos
immun
system
malt
contain
tcell
zone
bcell
enrich
area
contain
high
frequenc
sigaposit
b
cell
subepitheli
area
antigenpres
cell
induc
specif
immun
respons
mention
earlier
oral
mucosa
lack
certain
immunolog
structur
observ
peyer
patch
intestin
antigen
sampl
special
cell
howev
differ
studi
describ
concept
oral
lymphoid
foci
equival
germin
center
observ
malt
suggest
oral
mucosa
serv
site
immun
induct
role
oral
dc
decid
whether
induc
adapt
immun
toler
whether
exist
germin
center
oral
lymphoid
foci
discuss
extens
other
distribut
immun
cell
particularli
abund
presenc
oral
lc
make
oral
mucosa
attract
site
vaccin
deliveri
sublingu
buccal
immun
abl
promot
mucos
immun
well
system
immun
pathogen
enter
human
bodi
distant
site
mouth
mucosa
respiratori
tract
reproduct
tract
tabl
section
describ
use
live
attenu
pathogen
recombin
heterolog
express
inactiv
vaccin
furthermor
outlin
adjuv
ie
immun
potenti
andor
deliveri
system
evalu
vaccin
via
sublingu
buccal
rout
summari
publish
studi
sublingu
buccal
vaccin
given
tabl
sublingu
immun
mice
live
attenu
influenza
viru
strain
found
safe
effect
induc
protect
immun
respons
mucos
system
compart
song
et
al
conclud
observ
protect
mediat
induct
influenza
virusspecif
igg
serum
secretori
iga
siga
respiratori
mucosa
limit
viru
entri
replic
respiratori
tract
singl
sublingu
dose
viru
prevent
lung
patholog
induc
influenza
viru
challeng
provid
broadrang
crossprotect
differ
influenza
viru
subtyp
therebi
risk
potenti
passag
vaccin
viru
olfactori
bulb
avoid
use
sublingu
rout
sinc
viral
rna
detect
brain
sublingu
vaccin
mice
contrast
mice
receiv
vaccin
intranas
similarli
sublingu
administr
liveattenu
viru
lack
nonstructur
protein
protect
influenza
viru
challeng
mice
intranas
immun
sublingu
immun
virus
induc
high
level
virusspecif
antibodi
stimul
immun
cell
mucosaassoci
system
lymphoid
organ
moreov
vaccin
well
toler
induc
bodyweight
loss
sublingu
vaccin
mice
replicationdefect
adenoviru
vector
radv
wide
explor
deliveri
antigen
infect
adenovirus
occur
airway
epithelium
replic
take
place
mucos
tissu
respiratori
tract
characterist
make
vector
suitabl
mucos
vaccin
deliveri
sublingu
immun
radv
encod
conserv
influenza
nucleoprotein
antigen
solubl
globular
head
hemagglutinin
protect
mice
influenza
viru
infect
furthermor
sublingu
administr
vector
encod
hiv
protein
induc
signific
antigenspecif
humor
serum
mucos
igg
iga
cellular
system
mucos
ctl
respons
immun
respons
moreov
sublingu
vaccin
radv
encod
truncat
protein
radv
major
antigen
protein
present
sever
acut
respiratori
syndromeassoci
coronaviru
sarscov
induc
system
neutral
antibodi
airway
iga
antibodi
respons
mice
immun
respons
similar
induc
intranas
administr
worth
note
intranas
deliveri
radv
redirect
viru
vector
olfactori
bulb
wherea
adenovir
dna
detect
sublingu
deliveri
choi
et
al
report
mice
guinea
pig
protect
lethal
ebola
challeng
singl
sublingu
immun
advbas
vaccin
express
zair
glycoprotein
manner
similar
tradit
intramuscular
vaccin
avail
genet
tool
heterolog
gene
express
concept
live
vaccin
vehicl
spark
renew
interest
especi
mucos
rout
sever
studi
shown
engin
bacillu
b
subtili
abl
gener
system
mucos
antibodi
heterolog
antigen
b
subtili
deliv
sublingu
express
tetanu
toxin
cfragment
evok
protect
immun
mice
piglet
batista
et
al
report
use
gutcolon
b
subtili
spore
new
mucos
vaccin
deliveri
platform
consist
two
antigen
express
strategi
one
activ
spore
format
lead
display
recombin
adhesin
spore
surfac
facilit
adhes
mucos
surfac
addit
recombin
spore
shown
germin
oral
deliveri
result
intracellular
express
antigen
mice
immun
three
dose
b
subtili
spore
via
sublingu
rout
develop
higher
specif
serum
igg
titer
compar
mice
oral
immun
ninefold
higher
dose
spore
strain
although
proven
studi
author
specul
sublingu
deliveri
spore
also
result
intracellular
antigen
express
captur
intraepitheli
antigenpres
cell
germin
better
immun
respons
sublingu
vaccin
might
ascrib
fact
sublingu
deliveri
smaller
distribut
volum
less
aggress
environ
gastrointestin
deliveri
studi
cho
et
al
differ
rout
ie
intranas
intravagin
transderm
sublingu
intramuscular
compar
mous
studi
use
human
papillomaviru
protein
vaccin
among
rout
intranas
sublingu
rout
provid
highest
level
vagin
siga
system
igg
respons
compar
elicit
via
intramuscular
rout
sublingu
vaccin
respiratori
syncyti
viru
rsv
purifi
g
protein
fragment
gcf
without
addit
adjuv
induc
strong
serum
igg
mucos
iga
respons
similar
intranas
vaccin
mice
interestingli
antibodi
respons
could
elicit
gcf
without
need
adjuv
studi
demonstr
chemotact
activ
exhibit
gcf
necessari
induc
protect
immun
therefor
author
propos
gcf
selfadjuv
properti
murugappan
et
al
investig
whether
sublingu
administr
whole
bpl
inactiv
influenza
viru
prime
immun
system
later
intramuscular
boost
heterolog
vaccin
although
sublingu
prime
induc
detect
immun
respons
strongli
enhanc
hemagglutin
inhibit
hi
titer
homolog
well
heterolog
vaccin
intramuscular
booster
addit
sublingu
prime
induc
iga
respons
lung
nose
intramuscular
prime
show
higher
iga
respons
lung
nose
studi
song
et
al
sublingu
booster
given
instead
intramuscular
booster
immun
respons
analyz
extens
immun
formalininactiv
influenza
viru
via
sublingu
mucosa
induc
protect
immun
respons
elev
mucos
siga
antibodi
level
enhanc
virusspecif
ctl
respons
differ
procedur
use
viru
inactiv
affect
membran
fusion
properti
viru
certain
extent
result
less
optim
activ
ctl
inactiv
formalin
sever
compromis
fusion
activ
viru
bplinactiv
reveal
preserv
fusion
activ
howev
sublingu
booster
vaccin
formalininactiv
influenza
induc
signific
elev
virusspecif
ctl
respons
mice
unfortun
analysi
ctl
activ
lack
studi
use
bplinactiv
influenza
mucos
immun
gener
sublingu
buccal
vaccin
nonrepl
antigen
induc
siga
serum
igg
respons
without
addit
adjuv
strong
immun
potenti
deliveri
system
need
break
mucos
toler
facilit
uptak
oral
mucosa
exampl
mucos
adjuv
cholera
toxin
ct
need
induc
immun
respons
upon
sublingu
immun
human
immunodefici
viru
hiv
subunit
vaccin
et
al
evalu
sublingu
rout
vaccin
deliveri
use
ovalbumin
ova
model
antigen
mice
receiv
three
dose
ova
although
system
igg
respons
measur
mucos
ovaspecif
antibodi
respons
absent
sublingu
immun
ova
alon
coadministr
mucos
adjuv
ct
gener
high
ovaspecif
iga
respons
saliva
nasal
wash
respons
magnitud
induc
intranas
administr
recent
sublingu
administr
subunit
influenza
vaccin
evalu
mice
three
dose
detect
rather
low
antigenspecif
system
igg
hi
titer
found
sublingu
immun
wherea
mucos
iga
antibodi
detect
limit
addit
mucos
adjuv
need
obtain
convent
intramuscular
immun
salmonella
vaccin
consist
sonic
salmonella
protein
induc
protect
sublingu
immun
presenc
adjuv
cpg
dna
ct
observ
adult
neonat
mice
although
mucos
adjuv
improv
immun
respons
upon
sublingu
immun
use
nonreplicatinginactiv
antigen
studi
system
andor
mucos
immun
obtain
sublingu
deliveri
nonadjuv
inactiv
subunit
vaccin
gener
high
dose
use
even
size
antigen
seem
issu
success
immun
sinc
small
proteinsantigen
show
induct
system
mucos
immun
respons
upon
sublingu
administr
continu
next
page
adjuv
effect
sublingu
administ
ct
document
number
antigen
includ
influenza
hiv
subunit
vaccin
salmonella
protein
helicobact
pylori
lysat
latter
two
undefin
vaccin
lt
coadminist
sublingu
tetanu
toxoid
tt
induc
higher
specif
igg
mucos
iga
antibodi
titer
compar
tt
alon
howev
ct
lt
caus
sever
diarrhea
human
involv
clinic
occurr
cholera
enterotoxigen
e
coli
enter
therefor
suitabl
oral
sublingu
adjuv
human
use
sinc
enterotox
mainli
caus
enzymat
activ
asubunit
mutat
enterotoxin
reduc
toxic
retain
adjuv
properti
develop
lt
also
name
mlt
show
reduc
toxic
mice
maintain
adjuvant
level
nearli
equival
lt
build
mutant
doubl
mutant
lt
dmlt
show
adjuvant
coadminist
antigen
equival
mlt
upon
oral
administr
gastrointestin
deliveri
recent
dmlt
evalu
adjuv
sublingu
buccal
vaccin
wholecel
pneumococc
vaccin
induc
protect
mice
search
altern
adjuv
h
pylori
lysat
vaccin
dmlt
compar
ct
earlier
studi
shown
strong
mucos
adjuv
like
ct
need
induc
protect
immun
respons
h
pylori
infect
sublingu
immun
h
pylori
lysat
dmlt
significantli
decreas
bacteri
burden
h
pylori
infect
compar
unimmun
mice
extent
use
ct
adjuv
moreov
cellular
immun
respons
known
correl
protect
also
fulli
compar
use
dmlt
ct
adjuv
studi
cho
et
al
protein
provid
vagin
salivari
siga
serum
igg
respons
sublingu
administr
mice
sever
adjuv
test
includ
b
subunit
cholera
toxin
ctb
three
tolllik
receptor
agonist
ie
poli
c
mpl
imiquimod
three
nucleotidebind
oligomerizationdomain
agonist
murabutid
pgn
vitamin
polygammaglutam
acid
among
adjuv
test
ctb
provid
improv
mucos
siga
system
igg
induct
sublingu
appli
ctb
also
enhanc
product
ifni
stimul
cell
spleen
well
number
ifni
produc
cell
isol
spleen
submandibular
lymph
node
smln
adjuv
effect
immun
respons
compar
unadjuv
control
despit
neg
result
mention
tlr
agonist
significantli
improv
immun
respons
sublingu
vaccin
mous
studi
evalu
tlr
agonist
ie
poli
c
monophosphoryl
lipid
mpla
cytosinephosphateguanosin
cpg
differ
mucos
rout
use
hiv
tetanu
toxoid
reveal
clear
differ
immunogen
mpla
agonist
suppress
system
respons
administ
sublingu
respons
enhanc
intranas
subcutan
immun
cpg
ligand
evok
enhanc
immun
respons
upon
sublingu
intranas
immun
wherea
affect
respons
subcutan
immun
anoth
studi
reveal
sublingu
immun
vector
express
tlr
agonist
deriv
eimeriatenella
significantli
activ
nk
cell
natur
killer
nkt
cell
b
cell
cell
spleen
addit
number
cell
express
mhcii
increas
bacteri
dna
synthet
oligodeoxynucleotid
odn
contain
cpg
motif
act
mucos
adjuv
tlr
ligand
induc
strong
respons
mice
sublingu
deliveri
salmonella
vaccin
viruslik
particl
vlp
virosom
evalu
sublingu
deliveri
cho
et
al
show
sublingu
deliveri
vlp
mice
induc
system
igg
mucos
siga
respons
similar
intranas
rout
significantli
higher
compar
deliveri
intravagin
transderm
intramuscular
rout
contrast
studi
mice
clinic
trial
huo
et
al
sanofi
pasteur
contain
vlp
hpv
coadminist
aluminum
hydroxyphosph
adjuv
show
sublingu
immun
much
less
effect
intramuscular
immun
howev
alum
adjuv
vlp
formul
suitabl
sublingu
hpv
vaccin
like
due
fact
alum
adjuv
consist
rel
larg
micromet
rang
particl
probabl
poorli
taken
mucos
epitheli
cell
adjuv
well
improv
dosag
form
see
section
may
help
increas
immun
respons
vlp
sublingu
vaccin
contain
influenza
virosom
ha
combin
mucos
adjuv
cyclic
diguanyl
acid
cdigmp
effect
induc
local
system
humor
cellular
immun
respons
mice
system
igg
nasal
siga
antibodi
level
lower
induc
intranas
administr
igg
level
compar
obtain
intramuscular
administr
wherea
nasal
siga
level
higher
level
upon
intramuscular
administr
optim
dosag
form
may
improv
perform
sublingu
buccal
vaccin
substanti
sever
dosag
form
exist
sublingu
buccal
deliveri
market
drug
rang
droplet
spray
oral
disintegr
tablet
oral
film
howev
dosag
form
use
explor
sublingu
buccal
deliveri
vaccin
almost
sublingu
vaccin
studi
report
perform
simpl
applic
droplet
vaccin
tongu
studi
role
potenti
crucial
variabl
like
contact
time
vaccin
viscos
antigen
releas
kinet
immunogen
preclin
studi
vaccin
droplet
appli
tongu
floor
mouth
anim
kept
sedat
less
h
allow
vaccin
taken
see
tabl
sublingu
vaccin
mice
appli
sublingu
without
transfer
vaccin
stomach
includ
sedat
time
min
sublingu
administr
allergen
human
droplet
use
year
europ
sublingu
immun
therapi
slit
allergi
typic
slit
droplet
highli
viscou
glycerol
formul
contain
allergen
extract
appli
tongu
high
viscos
contribut
antigen
retent
tongu
facilit
efficaci
immun
therapi
recent
clinic
trial
hpv
vaccin
appli
sublingu
human
compar
slit
glycerol
droplet
rel
complic
administr
protocol
use
studi
brief
subject
rins
mouth
water
sublingu
area
dri
ml
vaccin
appli
floor
mouth
adsorb
pad
appli
mouth
absorb
saliva
vaccin
applic
despit
elabor
administr
protocol
three
twelv
subject
virusneutr
antibodi
induc
serum
three
standard
dose
hpv
vaccin
via
sublingu
rout
neutral
antibodi
titer
still
lower
intramuscular
group
research
conclud
altern
deliveri
system
adjuv
would
requir
enhanc
evalu
immun
respons
follow
sublingu
immun
human
disappoint
result
clinic
trial
may
relat
sever
factor
first
signific
amount
solut
ml
versu
coupl
droplet
slit
therapi
appli
despit
extens
administr
protocol
certain
high
volum
easili
digest
follow
gastrointestin
rout
secondli
vaccin
use
studi
vlp
base
vaccin
contain
aluminum
hydroxyphosph
sulfat
adjuv
alumadsorb
vaccin
larg
particl
size
rang
thu
ideal
transfer
membran
final
alum
known
good
adjuv
mucos
vaccin
droplet
improv
extend
mucos
retent
current
develop
path
technolog
base
thermorespons
gel
undisclos
composit
vaccin
present
liquid
solut
room
temperatur
enabl
sublingu
deliveri
oral
dropper
transform
gel
upon
contact
oral
mucosa
typic
thermorespons
gel
formul
gelat
temperatur
base
polym
poloxam
mucoadhes
polysaccharid
gel
matrix
enabl
adher
retent
n
min
sublingu
mucosa
therebi
prevent
rapid
clearanc
caus
saliv
swallow
protect
vaccin
antigen
degrad
caus
salivari
enzym
vaccin
mice
gel
formul
contain
tetanu
toxoid
elicit
high
level
igg
iga
serum
well
secret
mouth
gastrointestin
reproduct
tract
current
path
evalu
preclin
whether
addit
mucos
adjuv
dmlt
contribut
efficaci
sublingu
vaccin
use
thermorespons
gel
formul
sublingu
spray
use
year
sublingu
administr
nitroglycerin
patient
order
counter
acut
angina
pectori
use
nitroglycerin
spray
base
formul
contain
drug
substanc
ethanol
small
amount
mint
oil
propel
like
tetrafluoroethan
aerosol
formul
awar
investig
direct
spray
vaccin
onto
sublingu
buccal
mucosa
studi
howev
appli
vaccin
spray
whole
mouth
immun
human
influenza
whole
inactiv
viru
without
addit
oral
spray
use
simpl
nasal
spray
devic
use
propel
result
iga
antibodi
respons
nasal
secret
result
margin
increas
iga
antibodi
saliva
although
stimul
cytotox
cell
shown
increas
system
influenzaspecif
antibodi
found
extent
immun
respons
elicit
sublingu
vaccin
result
direct
immun
activ
tonsil
remain
matter
debat
exampl
shown
direct
immun
via
tonsil
give
rise
adequ
immun
respons
oral
spray
immun
replicationdefici
viral
vector
vaccin
encod
simian
immunodefici
viru
siv
spray
directli
tonsil
rhesu
macaqu
induc
cellular
humor
immun
respons
addit
siv
challeng
viral
rna
level
equal
reduc
system
vaccin
vaccin
use
oral
mucos
spray
sever
oral
formul
alreadi
licens
develop
drug
deliveri
mouth
base
drug
releas
kinet
manufactur
method
categor
oral
disintegr
prepar
tablet
fastdissolv
film
ii
extend
slow
releas
tablet
film
although
valu
sublingu
buccal
deliveri
antigen
yet
extens
evalu
describ
briefli
next
section
sinc
may
play
import
role
develop
potent
thermost
sublingu
vaccin
oral
disintegr
tablet
sublingu
buccal
deliveri
gener
rel
small
porou
tablet
buccal
deliveri
facilit
fast
disintegr
drug
vaccin
releas
without
inclus
disintegr
gener
tablet
dissolv
within
second
place
mouth
without
water
make
dri
stabl
altern
droplet
recent
sever
excipi
studi
wafer
format
abil
highli
porou
tablet
made
direct
compress
intent
formul
wafer
contain
hpv
vaccin
sublingu
vaccin
typic
fastdisintegr
formul
gener
wafer
diamet
mm
show
dissolut
time
less
ml
consist
approxim
ww
myoinositol
placebo
hpv
powder
microcrystallin
cellulos
mcc
effect
vaccin
via
sublingu
buccal
mucosa
contact
time
antigen
mucosa
expect
critic
although
remain
demonstr
sustain
releas
dosag
form
adher
mucosa
direct
transport
antigen
mucosa
may
improv
efficaci
sublingu
buccal
vaccin
regard
extend
releas
film
tablet
consist
multipl
layer
differ
function
fig
may
appli
sublingu
mucosa
expos
high
saliva
flow
might
advantag
better
swell
dissolut
oral
tablet
hand
might
also
caus
loss
antigen
adjuv
due
salivari
washout
therefor
much
lower
saliva
flow
buccal
mucosa
make
rout
probabl
better
target
sustain
releas
system
extend
releas
tablet
typic
base
gell
hydrophil
polym
socal
hydrophil
matrix
tablet
polym
form
gel
layer
around
tablet
make
contact
water
releas
profil
control
overal
swell
eros
polym
use
mucoadhes
hydrophil
polym
gelat
upon
contact
saliva
allow
adher
buccal
mucosa
interfaci
forc
hydrogen
bond
electrostat
interact
well
van
der
waal
bond
bord
et
al
prepar
extend
releas
tablet
model
antigen
ovalbumin
base
twolay
tablet
consist
mucoadhes
layer
compos
carbopol
control
releas
layer
sinc
tablet
abl
adher
floor
mouth
mice
tablet
appli
upsid
ventral
side
tongu
result
releas
antigen
toward
sublingu
region
immun
studi
perform
tablet
contain
ovalbumin
directli
follow
sublingu
administr
ct
solut
adjuv
immun
fastreleas
tablet
favor
extend
releas
formul
compar
liquid
refer
ovalbumin
ct
immun
respons
howev
product
saliva
induc
administ
pilocarpin
subcutan
administ
tablet
provid
better
swell
adhes
tablet
author
conclud
extend
releas
formul
sublingu
vaccin
investig
detail
extend
releas
formul
mice
optim
direct
antigen
toward
ventral
sublingu
mucosa
improv
antigen
diffus
prevent
salivari
washout
impact
enzym
shield
extend
releas
film
base
multipl
layer
gener
made
solvent
cast
method
antigen
ad
coat
mass
eg
cellulos
polysaccharid
subsequ
cast
onto
film
applic
apparatu
dri
solvent
evapor
film
cut
singl
dose
viscos
densiti
coat
mass
critic
success
film
cast
layerbylay
coat
moreov
vaccin
antigen
need
formul
coat
mass
proper
excipi
guarante
resist
appli
dri
stress
formul
proven
protect
vaccin
fabric
coat
solid
dosag
form
describ
literatur
yet
use
produc
vaccinecontain
film
exampl
group
prausnitz
appli
formul
base
trehalos
surfact
poloxam
polym
pvp
coat
microneedl
vaccin
whole
inactiv
influenza
viru
measl
dermal
vaccin
addit
advantag
dri
formul
improv
thermal
stabil
storag
oral
mucosa
particular
sublingu
buccal
region
attract
site
deliveri
antigen
sinc
access
noninvas
immunolog
advantag
mucos
rout
section
therefor
sublingu
vaccin
deliveri
gain
signific
attent
past
year
shown
numer
preclin
studi
publish
last
decad
tabl
preclin
proof
concept
sublingu
rout
vaccin
deliveri
proven
sever
antigen
gener
high
dose
antigen
administ
mice
use
multipl
dose
regimen
tabl
howev
welldesign
studi
includ
proper
dose
respons
track
pkpd
studi
still
lack
nevertheless
use
strong
mucos
adjuv
seem
necessari
induc
protect
immun
respons
upon
sublingu
vaccin
use
inactiv
vaccin
report
studi
screen
comparison
adjuv
sublingu
vaccin
unfortun
still
limit
adjuv
investig
thu
far
ct
ctb
lt
ltb
mlt
dmlt
cpg
cdigmp
poli
c
mpla
murabutid
peptidoglycan
vitamin
chitosan
polygammaglutam
acid
enterotoxin
mutant
agonist
result
highest
antibodi
respons
wherea
adjuv
improv
immun
respons
upon
sublingu
deliveri
use
adjuv
sublingu
vaccin
deliveri
enterotoxin
ct
lt
consid
toxic
human
use
howev
genet
defin
mutant
toxin
reduc
minim
toxic
seem
promis
adjuv
augment
system
mucos
immun
respons
sublingu
administr
recombin
live
carrier
express
vaccin
antigen
seem
elicit
protect
immun
induc
antigenspecif
system
well
mucos
antibodi
distinct
mucos
site
exact
advantag
live
vaccin
inactiv
vaccin
still
clear
could
relat
factor
receptormedi
uptak
intracellular
replic
antigen
codeliveri
immun
potenti
antigen
apc
approach
resembl
characterist
live
pathogen
eg
codeliveri
immun
potenti
antigen
need
develop
effect
inactiv
subunit
vaccin
sublingu
rout
unfortun
date
limit
studi
focus
approach
use
tailor
formul
nanoparticl
conjug
antigenadjuv
formul
design
formul
mucoadhes
receptorbind
properti
may
built
increas
interact
oral
mucosa
therebi
facilit
antigen
uptak
addit
deliveri
system
dosag
form
may
improv
efficaci
sublingu
buccal
vaccin
today
research
dosag
form
optim
sublingu
buccal
vaccin
appear
margin
report
studi
use
mous
model
evalu
sublingu
vaccin
vivo
nevertheless
small
space
tongu
anim
use
preclin
studi
make
test
sublingu
solid
dosag
form
challeng
exampl
muragappan
et
al
face
problem
sublingu
tablet
abl
dissolv
tongu
mice
moreov
twolay
extend
releas
tablet
fail
adher
floor
mouth
mice
result
suboptim
administr
appli
tablet
upsid
ventral
side
tongu
potenti
problem
relat
sublingu
applic
slow
releas
formul
due
lack
expans
smooth
rel
immobil
mucosa
make
difficult
keep
dosag
form
contact
sublingu
mucosa
dosag
form
wafer
film
thermorespons
gel
explor
may
like
increas
potenti
sublingu
vaccin
deliveri
sustain
dosag
form
eg
multilay
oral
film
tablet
probabl
better
suit
applic
buccal
mucosa
consider
less
permeabl
sublingu
mucosa
current
studi
buccal
vaccin
deliveri
use
buccal
inject
instead
topic
applic
howev
develop
extend
releas
formul
would
make
topic
buccal
cheek
vaccin
easier
compar
sublingu
rout
buccal
administr
small
anim
mice
complic
sinc
buccal
compart
minim
anatom
barrier
sublingu
compart
besid
anim
size
anatom
featur
oral
caviti
taken
account
special
histolog
characterist
immunolog
compet
oral
mucosa
human
howev
rodent
mice
rat
hamster
buccal
mucosa
contain
keratin
epithelium
contrast
nonkeratin
epithelium
sublingu
cheek
mucosa
human
buccal
cheek
administr
anim
model
rabbit
dog
pig
appropri
sinc
contain
nonkeratin
buccal
mucosa
moreov
thick
buccal
mucosa
anim
model
rabbit
dog
pig
compar
human
current
literatur
address
extent
mucoadhes
formul
increas
deliveri
antigen
oral
mucos
apc
sublingu
buccal
administr
requir
proper
track
pharmacokinet
pk
studi
relat
immunolog
outcom
pharmacodynam
pd
adequ
anim
model
tabl
select
suitabl
formul
dosag
form
vitro
model
mucosa
predict
transport
antigen
might
use
porcin
buccal
mucosa
often
chosen
vitro
studi
buccal
deliveri
medicin
close
resembl
human
buccal
mucosa
respect
structur
enzym
activ
well
permeabl
characterist
howev
mechanist
studi
evalu
condit
sublingu
buccal
antigen
deliveri
optim
contact
time
dosag
form
differ
oral
mucos
rout
lack
literatur
moreov
import
specif
molecular
featur
antigen
andor
antigen
formul
size
eg
nm
protein
versu
nm
virus
versu
bacteria
surfac
charg
specif
receptor
ligand
still
investig
systemat
preclin
studi
vivo
anim
model
use
evalu
vaccin
candid
effici
induc
protect
mucos
system
immun
secretori
iga
siga
provid
antigenspecif
immun
protect
mucos
tissu
result
preclin
studi
sublingu
vaccin
includ
detect
siga
mucos
secret
unfortun
studi
design
optim
readout
system
immun
respons
make
assumpt
mucos
immun
fulli
conclus
moreov
gener
presenc
siga
determin
saliva
best
readout
mucos
immun
especi
rodent
predict
method
measur
mucos
immun
mucos
tissu
rodent
perfext
method
direct
method
quantit
assess
vivo
antibodi
cytokin
product
local
level
method
use
collect
heparin
mucos
tissu
anim
follow
deterg
treatment
detect
antigenspecif
antibodi
elisa
base
sever
preclin
studi
would
highli
interest
follow
expect
upcom
clinic
studi
sublingu
vaccin
deliveri
use
live
attenu
vaccin
studi
build
experi
previou
preclin
studi
design
evalu
mucos
immun
correl
protect
would
requir
standard
valid
assay
predict
mucos
immun
protect
exampl
method
describ
saletti
et
al
allow
measur
system
mucos
antibodi
respons
vaccin
detect
antigenspecif
plasmablast
specif
mucos
pedigre
eg
small
amount
whole
blood
although
develop
clinic
sampl
certain
type
mucos
readout
would
also
use
preclin
studi
amid
limit
blood
volum
sequenti
withdrawn
small
anim
full
benefit
sublingu
vaccin
reveal
determin
local
system
respons
current
literatur
sublingu
buccal
vaccin
broad
rang
antigen
provid
strong
base
test
noninvas
vaccin
deliveri
rout
test
includ
mechanist
studi
superior
live
vaccin
inactiv
antigen
includ
doserespons
studi
tabl
base
find
tailor
vaccin
formul
inactiv
antigen
may
design
near
futur
develop
sophist
formul
optim
dosag
form
facilit
antigen
uptak
oral
mucosa
import
step
forward
toward
success
sublingu
andor
buccal
vaccin
final
upcom
clinic
studi
confirm
suggest
safeti
effici
proper
readout
mucos
system
immun
may
result
first
approv
sublingu
vaccin
strategi
